Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
urogenital diseases | D000091642 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Padcev | enfortumab vedotin-ejfv | Astellas Pharma | N-761137 RX | 2019-12-18 | 2 products |
Brand Name | Status | Last Update |
---|---|---|
padcev | Biologic Licensing Application | 2025-02-28 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
urinary bladder neoplasms | — | D001749 | C67 |
Code | Description |
---|---|
J9177 | Injection, enfortumab vedotin-ejfv, 0.25 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Transitional cell carcinoma | D002295 | — | — | 3 | 6 | — | 1 | 1 | 10 |
Urologic neoplasms | D014571 | — | C64-C68 | 1 | 4 | — | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urinary bladder neoplasms | D001749 | — | C67 | 4 | 7 | 3 | — | — | 11 |
Ureteral neoplasms | D014516 | EFO_0003844 | C66 | 1 | 3 | 1 | — | — | 4 |
Muscle neoplasms | D019042 | — | C49 | — | — | 1 | — | — | 1 |
Drug common name | Enfortumab vedotin |
INN | enfortumab vedotin |
Description | Enfortumab vedotin (human mab) |
Classification | Antibody |
Drug class | synthetic analogs of the dolastatin series; monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3301589 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB13007 |
UNII ID | DLE8519RWM (ChemIDplus, GSRS) |